Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Liabilities: 2013-2025

Historic Total Liabilities for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $152.7 million.

  • Ocular Therapeutix's Total Liabilities rose 10.34% to $152.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.7 million, marking a year-over-year increase of 10.34%. This contributed to the annual value of $142.6 million for FY2024, which is 11.40% down from last year.
  • Per Ocular Therapeutix's latest filing, its Total Liabilities stood at $152.7 million for Q3 2025, which was up 4.98% from $145.4 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Total Liabilities peaked at $160.9 million during Q4 2023, and registered a low of $107.3 million during Q2 2022.
  • Its 3-year average for Total Liabilities is $140.3 million, with a median of $140.0 million in 2025.
  • Data for Ocular Therapeutix's Total Liabilities shows a peak YoY increase of 91.14% (in 2021) and a maximum YoY decrease of 37.08% (in 2021) over the last 5 years.
  • Ocular Therapeutix's Total Liabilities (Quarterly) stood at $116.9 million in 2021, then declined by 2.55% to $113.9 million in 2022, then spiked by 41.28% to $160.9 million in 2023, then fell by 11.40% to $142.6 million in 2024, then grew by 10.34% to $152.7 million in 2025.
  • Its last three reported values are $152.7 million in Q3 2025, $145.4 million for Q2 2025, and $140.0 million during Q1 2025.